Form 4: Guided Therapeutics Director Acquires Additional Shares Through Dividend Conversion

Director John E. Imhoff increased his holdings in Guided Therapeutics through the conversion of accrued dividends from Series F and Series D preferred stock into common stock.

Summary

• On March 26, 2024, John E. Imhoff acquired 4,420 shares of common stock due to accrued dividends on Series F preferred stock at a conversion price of $0.1361 per share, increasing his direct holdings to 5,129,258 shares.
• On April 5, 2024, Imhoff acquired an additional 48,638 shares of common stock due to accrued dividends on Series D preferred stock at a conversion price of $0.1157 per share, bringing his total direct holdings to 5,177,896 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions related to dividend conversions, which are part of the company's existing financial structure. There is no indication of significant positive or negative news.

Positives

• The director's increased stake could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities, allowing investors to monitor the actions of company insiders.

Stakeholder Impact

• The increased holdings by a director could be viewed positively by shareholders, potentially increasing investor confidence.

Key Dates

Keywords

Guided Therapeutics, GTHP, John E. Imhoff, Director, Share Acquisition, Dividend Conversion, Series F Preferred Stock, Series D Preferred Stock, Beneficial Ownership, Form 4